Advances in surgery have always been married to advances in technology. The unprecedented boom in biotechnology in the past few decades has had a tremendous impact on almost every aspect of surgery. Surgical training, OR ergonomics, surgical technique and post-surgical care have all benefited substantially. While the perceived impact on the surgical community has been uniformly positive, whether this has objectively translated into better patient related outcomes is still a matter of debate.
In this meeting, we will be presenting the most robust data from a carefully curated selection of technology, which we feel have had the maximum impact on surgery. We will touch upon different aspects of surgical technology like the use of simulators and virtual reality in surgical training, image guided and augmented optics guided surgery, 3D printing in reconstructive surgery and robotics.
We hope to initiate a discussion, from which we aim to emerge with a more nuanced understanding of surgical technology and achieve some consensus on its best utilization in optimizing patient care.
Precision oncology has been a major driver of success in the last decade which is attributed to rapidly evolving genomics and clinical research. The field has evolved from a tumor centric approach to a target specific tumor independent approach. It has reached from territories of refractory disease which is a major unmet need to diseases where chemotherapy has not made an impact. There is an element of hype along with hope in this field. There is skepticism even in the developed world as far as cost-efficacy is concerned and it is getting increasingly difficult to draw the line demarcating hope from hype... This question is far more important for LMICs like India, where there is limited technology, infrastructure and finances. This section of EBM will bridge the gap between hope and hype and attempt to formulate a consensus for LMICs in precision oncology.
The last two decades have witnessed an unprecedented pace in unveiling of advancements in technology. Every aspect of Radiation Oncology has been touched and enhanced by these innovations like never before.
Right from immobilization, imaging, planning, motion management, delivery guidance methods to patient – care provider team pathways, quality and patient safety have been influenced. At times the churn has been so rapid and rigorous that it could have influenced even the most stoic minds. We have witnessed this even in India and very soon we are also going to start the first public sector proton treatment facility in India, at TMC, Mumbai.
This is an opportune time to take a pause and reflect upon the real gains with the leaps of advancements in terms of evidence and its impact on practice, quality, outcomes, patient safety and cost. Let us all get together at this yearly deliberation for the year 2020-21, and generate a blue print applicable to our socio-economic, cultural and epidemiological plethora. We hope, this would give direction to future research and innovations indigenously, best suiting our needs.
Like always, we promise to bring to you the who’s who nationally and internationally in these fields, covering various modules on photons, protons, artificial intelligence and their implications and application to Radiation Oncology today and where we envisage its place in the years to come. With the theme of the meeting being technology, we bring you a high tech online meeting and hope you have the best possible experience.
The concept of ‘Theranostics’ has emerged strongly over the last decade, Theranostics involves the coupling of diagnostic biomarkers with therapeutic agents that share a specific target in cancer cells. Theranostics in nuclear medicine refers to the use of radioactive compounds to image biologic processes by means of expression of specific disease targets such as cell surface receptors or membrane transporters, and then to use specifically designed agents to deliver ionizing radiation to the tissues that express these targets.With synthesis of smaller peptides, ligands and antibody fragments, and uncovering newer pathways for tumor targeting, use of radio-ligands for therapy has come into spotlight. Prospective trials have established the role of Lu-177 based therapy in the treatment algorithm of neuroendocrine tumors and metastatic prostate cancer. Apart from established theranostics, there is strong emergence of newer radioisotopes with theranostic potential, which are slowly moving from bench to bedside.
We thereby aim to focus on providing an evidence based perspective on Nuclear Theranostics with lectures and discussions by eminent International and National Faculty.
Nuclear Medicine Physicians
Peptide receptor radionuclide therapy and combinations therapies in neuroendocrine neoplasms
Theranostics of prostate cancer: mCRPC, upfront therapy and Alpha PSMA therapy
Emerging theranostics: Lymphoma, Breast cancer and Neuroblastoma.
Trans-arterial radioembolisation (TARE)
The intertwining of Technology and Artificial Intelligence with Healthcare keeps growing exponentially. Radiology has been at the forefront of the intersection of health and technology since the introduction of CT in the 1980s, and has been amongst the early adopters of AI both in research and clinical practice, boasting of amongst the first FDA approved AI products and a dedicated AI in Radiology journal. The potential for AI in the era of precision oncology is tremendous, with important diagnostic, prognostic and management implications. However, bridging the gap between promise and delivery remains a challenge, as the AI ecosystem and technology needs time to mature. For AI to truly reach its potential and become an inseparable companion of the radiologist, we need to chart a course for the future which includes testing the technology with the same scientific rigor as we would another product or drug. Besides AI, other exciting technologies such as augmented and virtual reality and 3D printing are also bound to create their niche in the future oncology arena. Furthermore, the impact of technology on improving machine and patient workflow, image quality and overall throughput are probably as game-changing as the applications on image interpretation. This conference will focus on the practical aspects of AI and technology in radiology, and create a roadmap for maximizing their potential impact on radiology and healthcare.
Department of Pathology, Tata Memorial Centre, is pleased to announce a two day virtual CME as a part of the Evidence Based Medicine (EBM) conference2021.
History of Surgical Pathology is a tale of three revolutions viz. immunohistochemistry, genomics and digital pathology. This CME will be a comprehensive update on the two frontier trans-disciplinary domains in pathology and provide valuable insights beyond conventional microscopy through the following tracks.
This event will concentrate on the core knowledge and recent advances in development, evaluation and implementation of innovative high complexity molecular diagnostic clinical tests. The CME will cover how data-driven, evidence-based methods are employed to develop and select new genomic diagnostic platforms and tests using advanced molecular technologies into the clinical setting.
The key areas of this CME will include:
It will benefit scientists, postgraduates in pathology, practising pathologists, oncologists to understand the most recent innovations, trends, concerns, practical challenges encountered, and solutions adopted in the field of Molecular Diagnostics.
Digital pathology and its applications (CP/AI) are ushering a revolution fuelled by advances in deep learning and computing technology.
The CME will cover basics, latest advances and future directions over the following key areas:
1) Establishing and Transitioning to Digital Pathology,
2) Pre-Imaging Factors for Digital Pathology and AI
3) AI algorithms in digital pathology and Translational Medicine.
This CME would be of interest to researchers and computational scientists and a “must attend” for all budding pathologists and practicing pathologists.